The World Health Organization has issued new global guidelines advising against the use of obesity drugs in children under 10, emphasizing that healthy eating and regular exercise should remain the primary focus of weight‑management strategies.

The guidelines, released by WHO, caution that medications such as weight‑loss injections carry uncertain safety profiles in young children and may distract from proven non‑pharmacological approaches. Health experts argue that early intervention through diet, physical activity, and behavioral support can prevent long‑term health complications without exposing children to potential drug‑related risks.

Childhood obesity has risen worldwide, contributing to increased rates of type 2 diabetes, hypertension and psychosocial issues. While pharmaceutical options are available for adults, the evidence base for pediatric use remains limited. WHO stresses that clinicians should prioritize counseling, community programs and school‑based initiatives to create supportive environments for healthy growth.

The new recommendations come at a time when some countries are exploring prescription weight‑loss treatments for youth. By redirecting resources toward preventive care, the organization hopes to curb the obesity epidemic and reduce the burden on health systems. Researchers and policymakers will need to monitor the impact of these guidelines and explore safe, effective interventions that can be tailored to children’s unique developmental needs.

Parents, caregivers and health professionals are urged to stay informed about the latest evidence and to collaborate with multidisciplinary teams. The WHO also calls for stronger regulation of over‑the‑counter supplements marketed to children, as well as improved surveillance of prescription practices. Future studies will be essential to evaluate the long‑term outcomes of lifestyle interventions compared with pharmacotherapy in early childhood.